As of close of business last night, Caredx Inc’s stock clocked out at $10.32, down -2.55% from its previous closing price of $10.59. In other words, the price has decreased by -$0.27 from its previous closing price. On the day, 552202 shares were traded.
Ratios:
To gain a deeper understanding of CDNA’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.77 and its Current Ratio is at 4.02. In the meantime, Its Debt-to-Equity ratio is 0.13 whereas as Long-Term Debt/Eq ratio is at 0.11.
On August 15, 2023, Raymond James Upgraded its rating to Outperform which previously was Mkt Perform but kept the price unchanged to $12.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Oct 02 ’23 when Seeto Reginald sold 2,818 shares for $6.91 per share. The transaction valued at 19,483 led to the insider holds 479,164 shares of the business.
Seeto Reginald sold 2,819 shares of CDNA for $26,762 on Sep 05 ’23. The insider now owns 481,982 shares after completing the transaction at $9.49 per share. On Aug 14 ’23, another insider, Seeto Reginald, who serves as the insider of the company, sold 576 shares for $8.89 each. As a result, the insider received 5,123 and left with 484,801 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CDNA now has a Market Capitalization of 534.87M and an Enterprise Value of 333.68M. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.91 while its Price-to-Book (P/B) ratio in mrq is 2.03. Its current Enterprise Value per Revenue stands at 1.19 whereas that against EBITDA is -3.93.
Stock Price History:
The Beta on a monthly basis for CDNA is 1.42, which has changed by 21.44% over the last 52 weeks, in comparison to a change of 28.14% over the same period for the S&P500. Over the past 52 weeks, CDNA has reached a high of $12.93, while it has fallen to a 52-week low of $4.80. The 50-Day Moving Average of the stock is 9.70, while the 200-Day Moving Average is calculated to be 9.08.
Shares Statistics:
It appears that CDNA traded 978.40K shares on average per day over the past three months and 825.57k shares per day over the past ten days. A total of 51.50M shares are outstanding, with a floating share count of 49.43M. Insiders hold about 4.54% of the company’s shares, while institutions hold 99.22% stake in the company. Shares short for CDNA as of Mar 15, 2024 were 4.36M with a Short Ratio of 4.45, compared to 3.6M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 8.42% and a Short% of Float of 11.10%.
Earnings Estimates
As of right now, 5 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.19 for the current quarter, with a high estimate of -$0.17 and a low estimate of -$0.21, while EPS last year was -$0.11. The consensus estimate for the next quarter is -$0.14, with high estimates of -$0.09 and low estimates of -$0.18.
Analysts are recommending an EPS of between -$0.39 and -$0.68 for the fiscal current year, implying an average EPS of -$0.53. EPS for the following year is -$0.46, with 5 analysts recommending between -$0.19 and -$1.1.
Revenue Estimates
In the current quarter, 7 analysts expect revenue to total $63.5M. It ranges from a high estimate of $64.9M to a low estimate of $62M. As of the current estimate, Caredx Inc’s year-ago sales were $77.26M, an estimated decrease of -17.80% from the year-ago figure.
A total of 7 analysts have provided revenue estimates for CDNA’s current fiscal year. The highest revenue estimate was $269.06M, while the lowest revenue estimate was $264.1M, resulting in an average revenue estimate of $266.61M. In the same quarter a year ago, actual revenue was $280.32M, down -4.90% from the average estimate. Based on 6 analysts’ estimates, the company’s revenue will be $285.35M in the next fiscal year. The high estimate is $294.35M and the low estimate is $278.9M. The average revenue growth estimate for next year is up 7.00% from the average revenue estimate for this year.
